Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Oliver G. Ottmann, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Ariful Haque, Neil Gallagher, Francis Giles, MD

Blood (2007) 110 (11): 2815.

https://doi.org/10.1182/blood.V110.11.2815.2815

Published: 2007

Journal Articles

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Jorge Cortes, MD, Elias Jabbour, MD, Andreas Hochhaus, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Francis Giles, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1040.

https://doi.org/10.1182/blood.V110.11.1040.1040

Published: 2007

Journal Articles

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

Jason Gotlib, Tracy I. George, Chris Corless, Andrea Linder, Alisa Ruddell, Cem Akin, Daniel J. DeAngelo, Ilana Kepten, Carlo Lanza, Heidrun Heinemann, Ophelia Yin, Neil Gallagher, Tim Graubert

Blood (2007) 110 (11): 3536.

https://doi.org/10.1182/blood.V110.11.3536.3536

Published: 2007

Journal Articles

Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.

Francis J. Giles, MB, MD, FRCPI, FRCPath, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Philipp le Coutre, Michele Baccarani, MD, Ariful Haque, Neil Gallagher, Oliver G. Ottmann, MD

Blood (2007) 110 (11): 1025.

https://doi.org/10.1182/blood.V110.11.1025.1025

Published: 2007

Journal Articles

Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).

Francis J. Giles, MB, MD, FRCPI, FRCPath, Philipp le Coutre, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Giuliana Alimena, Ariful Haque, Neil Gallagher, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1029.

https://doi.org/10.1182/blood.V110.11.1029.1029

Published: 2007

Journal Articles

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Giuseppe Saglio, Dong-Wook Kim, Andreas Hochhaus, Simona Soverini, P. Erben, Susan Branford, Ariful Haque, Neil Gallagher, Yaping Shou, Timothy Hughes, G. Martinelli, Jerald Radich

Blood (2007) 110 (11): 1940.

https://doi.org/10.1182/blood.V110.11.1940.1940

Published: 2007

Journal Articles

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Philipp le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jane Apperley, MD, Oliver G. Ottmann, MD, Norbert Gattermann, MD, PhD, Stephen G. O’Brien, MD, PhD, Kazimierz Kuliczkowski, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 471.

https://doi.org/10.1182/blood.V110.11.471.471

Published: 2007

Journal Articles

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Jorge Cortes, MD, Giovanni Martinelli, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Philipp le Coutre, MD

Blood (2007) 110 (11): 735.

https://doi.org/10.1182/blood.V110.11.735.735

Published: 2007

NARROW

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.

Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only